Pieris Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference Sponsored by H C Wainwright (Virtual) Transcript
And we are moving on to our next presentation. Our next presenter is Stephen Yoder, who is the Chief Executive Officer, of Pieris. Pieris is focused on the development of Anticalin protein-based drugs, targeting cancer and respiratory diseases.
So please join me in welcoming Stephen Yoder.
Well, thank you, Emanuela. Thank you to H.C. Wainwright for the invitation to present today. And I'm happy to spend the next 15 minutes or so providing a corporate update on Pieris Pharmaceuticals.
For those of you who don't know us, we are a next-generation therapeutic protein company that has, as Emanuela mentioned, a proprietary class of molecules that we call Anticalins. And today, I want to focus our discussion on the clinical data we've generated with the 2 programs, PRS-060 and PRS-343. And then, more importantly, I want to discuss the planned upcoming clinical proof-of-concept trials for each of those programs. As I
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |